We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

To aim for £1,000 a month in passive income, should I buy growth shares or value shares?

Deciding which shares are the best to invest in is important when considering long-term passive income. However, there are several factors to consider.

| More on:
Passive income text with pin graph chart on business table

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Growth shares and value shares both offer returns that can equate to a decent amount of monthly passive income. While growth shares focus on growing the business and, subsequently, the share price, value shares try attract investment through dividends.

While growth shares can be more profitable and volatile, value shares typically provide a slow yet reliable source of income.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

So which is best for passive income?

Well, that depends.

It makes sense to shift focus towards dividend-paying (value) shares the closer one gets to retirement. This ensures regular payments are made throughout the year to support financial needs. But early investors who are financially stable could build a larger retirement pot from growth shares.

A portfolio of growth shares that increase at an average of 7% annually would need £171,000 invested to return £12,000 per year. Naturally, a portfolio of shares with an average 7% dividend yield would achieve similar returns. 

The trick is evaluating the growth prospects and the consistency of dividend payments to assess the best long-term option.

Evaluating a growth share

With a £237bn market cap, AstraZeneca (LSE: AZN) is one of the most popular pharmaceutical stocks on the FTSE 100. A recent earnings report revealed £47bn in revenue and £39bn in gross profit. It only has a 1.8% dividend yield but over the past 10 years, its share price has increased from £43 to £123. That equates to annualised returns of 11% per year. If it continues to grow at this rate, an investment of £10,000 would return £12,000 a year after 23 years.

But while AstraZeneca has been performing well, there is no guarantee it will continue. It faces the risk of patent expirations and strong competition from other major drug developers like Johnson & Johnson, Roche and Merck. One of AstraZeneca’s best-selling drugs, Farxiga, comes off patent in 2024. If a competitor releases a similar or better version of the drug, it could cost AstraZeneca $4.3bn in annual sales.

Evaluating a value share

By comparison, the HSBC (LSE: HSBA) share price has increased from £6.14 to £6.99 in the past 10 years – an annualised return of only 1.8%. Even though it has a high 7% dividend yield, it would take almost 30 years before it began paying out £12,000 a year. However, the dividend is expected to increase by around 0.2% per year, potentially making the stock a more profitable option in the long term.

But bank shares, while high value, pose other risks. When financial crises occur, they often bear the brunt of the losses. As it is, independent analysts estimate that HSBC’s earnings could decline at an average of 3% per year for the next three years. Reduced earnings could put pressure on the bank’s operating profits and negatively affect price performance.

The verdict

When looking to build a portfolio aiming for passive income, it’s often best to include a mix of growth and value shares. This is particularly important when looking at a long timeline of 30+ years. In this way, the portfolio could benefit from growth shares during strong economic periods and remain stable from value shares during tough times.

However, as retirement draws near, it may be beneficial to weight the portfolio more towards value shares. This should help to ensure a more stable and regular income from dividend payments.

HSBC Holdings is an advertising partner of The Ascent, a Motley Fool company. Mark Hartley has positions in AstraZeneca Plc and HSBC Holdings. The Motley Fool UK has recommended AstraZeneca Plc and HSBC Holdings. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Happy male couple looking at a laptop screen together
Investing Articles

Up 50% with a stunning 6.4% yield! How do Aviva shares do it?

Harvey Jones is hugely impressed by the recent performance of Aviva shares, and examines why the FTSE 100 insurer has…

Read more »

Satellite on planet background
Investing Articles

Down 19% to under £20! Is now exactly the right time for me to capitalise on BAE Systems’ bargain-basement share price?

BAE Systems’ share price has dropped sharply, but a far bigger long term demand cycle is only just beginning. Here’s…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Closing in on £33 and around an all‑time high, is this FTSE 250 favourite seriously mispriced?

With the shares pushing into record territory, I’ve revisited the underlying business, its growth outlook and the valuation picture investors…

Read more »

Close-up of British bank notes
Investing Articles

£20,000 invested in Barclays shares a year ago is now worth…

Barclays shares have quietly delivered a 41% return in just 12 months — and the long term numbers suggest the…

Read more »

Young black woman walking in Central London for shopping
Investing Articles

£9,000 in an ISA? Here’s how to target a £675 passive income with 7% investment trusts

Investment trusts can offer a huge and stable passive income every year. Royston Wild reveals three to consider -- including…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

These 3 shares could deliver a £1,840 second income in an ISA overnight!

With an average dividend yield of 9.2%, these top UK shares could deliver turn a £20,000 ISA into a huge…

Read more »

Wall Street sign in New York City
Investing Articles

Up 5.3%, the Dow Jones lags other US indices in 2026. Here’s why UK income investors should pay attention

Mark Hartley highlights how US indices blur the real market story with tech-driven hype, and why the Dow Jones matters…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£1,000 buys 531 shares in this UK defence and nuclear stock that’s tipped to soar

This UK stock offers growth and income at an attractive valuation. Could it be worth considering for an ISA or…

Read more »